{
    "clinical_study": {
        "@rank": "33412", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo."
            }, 
            {
                "arm_group_label": "ODM-102", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the safety and tolerability of escalating single\n      doses of ODM-102 in healthy volunteers"
        }, 
        "brief_title": "Safety and Tolerability Study With Single Ascending Doses of ODM-102", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent (IC) obtained.\n\n          -  Good general health ascertained by detailed medical history and physical examination.\n\n          -  Finnish-speaking males between 18 and 45 years of age (inclusive).\n\n          -  Body mass index (BMI) between 18.0-30.5 kg/m2 (inclusive).\n\n          -  Weight 55.0-100.0 kg (inclusive).\n\n        Exclusion Criteria:\n\n          -  Suspected poor compliance or inability to communicate well with the investigator.\n\n          -  Veins unsuitable for repeated venipuncture.\n\n          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,\n             gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or\n             psychiatric disease as judged by the investigator.\n\n          -  Any condition requiring regular concomitant drug treatment, including herbal\n             products, or likely to need any concomitant drug treatment during the study.\n\n          -  Susceptibility to severe allergic reactions.\n\n          -  Intake of any medication that could affect the outcome of the study within 2 weeks\n             prior to the first study drug administration or within less than 5 times the\n             elimination half-life of the medication.\n\n          -  Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits,\n             about 13 g of alcohol).\n\n          -  Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.\n\n          -  Inability to refrain from using nicotine-containing products during the stay in the\n             study centre.\n\n          -  Inability to refrain from consuming caffeine-containing beverages during the first 24\n             hours after treatment administration e.g. propensity to experience headache when\n             abstaining from caffeine-containing beverages.\n\n          -  Blood donation or loss of a significant amount of blood within 2 months prior to the\n             screening visit.\n\n          -  Abnormal 12-lead ECG finding of clinical relevance after 10 min rest in supine\n             position at the screening visit\n\n          -  HR < 45 beats/minute or > 90 beats/minute after 10 minutes rest in supine position at\n             the screening visit.\n\n          -  At the screening visit, systolic BP < 90 mmHg or > 140 mmHg after 10 minutes in\n             supine position, diastolic BP < 50 mmHg or > 90 mmHg after 10 minutes in supine\n             position, or symptomatic orthostatic hypotension, or decrease of \u2265 20 mmHg of\n             systolic BP or decrease of \u2265 10 mmHg of diastolic BP after 3 minutes in standing\n             position.\n\n          -  Abnormal 24-hour Holter ECG recording of possible or confirmed clinical relevance\n\n          -  Any abnormal laboratory value, vital sign, or physical examination finding, which may\n             in the opinion of the investigator interfere with the interpretation of the test\n             results or cause a health risk to the subject if he takes part in the study.\n\n          -  Suspected current use of illicit drugs (according to medical history enquiry or\n             physical examination), positive drug screen or history of long-term drug abuse.\n\n          -  Positive serology to human immunodeficiency virus antigen/antibodies (HIVAgAb),\n             hepatitis B virus surface antigen (HBsAg) or hepatitis C virus antibodies (HCVAb).\n\n          -  Participation in another clinical drug study within 3 months prior to the first\n             treatment administration in this study.\n\n          -  Any other condition that in the opinion of the investigator would interfere with the\n             evaluation of the results or constitute a health risk for the subject."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839019", 
            "org_study_id": "3099003"
        }, 
        "intervention": [
            {
                "arm_group_label": "ODM-102", 
                "description": "Single dose escalation", 
                "intervention_name": "ODM-102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single dose escalation", 
                "intervention_name": "Placebo for ODM-102", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Healthy volunteers", 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Turku", 
                    "country": "Finland", 
                    "zip": "20520"
                }, 
                "name": "Clinical Research Services Turku, CRST"
            }
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability and Pharmacokinetics of Single Escalating Doses of ODM-102: A Randomised, Double-blind, Placebo-controlled, Single Centre Study in Healthy Males", 
        "overall_official": {
            "affiliation": "Clinical Research Services Turku, CRST", 
            "last_name": "Mika Scheinin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Finland: Finnish National Agency for Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety measures, i.e. assessing adverse events, vital signs, ECG and safety laboratory values", 
            "safety_issue": "Yes", 
            "time_frame": "about a month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839019"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Explore the PK profile (e.g. Cmax, tmax, AUC, t1/2), screen circulating metabolites and determine protein binding.", 
            "measure": "Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "5 days per period"
        }, 
        "source": "Orion Corporation, Orion Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Orion Corporation, Orion Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}